The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 21, Pages 5388
Publisher
MDPI AG
Online
2022-11-02
DOI
10.3390/cancers14215388
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study
- (2022) Massimo Cristofanilli et al. CLINICAL CANCER RESEARCH
- CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
- (2022) Erik S. Knudsen et al. Cell Reports
- RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models
- (2022) Vishnu Kumarasamy et al. ONCOGENE
- Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
- (2021) Georgia Gomatou et al. MOLECULAR BIOLOGY REPORTS
- Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
- (2021) Paweł Łukasik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Steroid Hormone Receptors: Links With Cell Cycle Machinery and Breast Cancer Progression
- (2021) Suryendu Saha et al. Frontiers in Oncology
- Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women
- (2021) Binghe Xu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
- (2021) Hon Yan Kelvin Yip et al. Cells
- Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors
- (2021) Yassi Fallah et al. Frontiers in Oncology
- Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
- (2021) Michael Gnant et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
- (2021) Ying Li et al. Frontiers in Oncology
- SPH3643: A novel CDK4/6 inhibitor with good anti‐cancer efficacy and strong blood‐brain barrier permeability
- (2020) XueMei Liao et al. CANCER SCIENCE
- Cyclins E1 and E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets
- (2020) Heloisa Milioli et al. ENDOCRINE-RELATED CANCER
- The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
- (2020) Scott F. Schoninger et al. MOLECULAR CANCER THERAPEUTICS
- Therapy after cyclin‐dependent kinase inhibition in metastatic hormone receptor‐positive breast cancer: Resistance mechanisms and novel treatment strategies
- (2020) Marina N. Sharifi et al. CANCER
- The application and prospect of CDK4/6 inhibitors in malignant solid tumors
- (2020) Qi Du et al. Journal of Hematology & Oncology
- Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis
- (2020) Francesco Schettini et al. JNCI-Journal of the National Cancer Institute
- Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
- (2020) William J. Gradishar et al. Journal of the National Comprehensive Cancer Network
- Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
- (2020) Richard S. Finn et al. BREAST CANCER RESEARCH AND TREATMENT
- Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
- (2020) Nicola Gaynor et al. SEMINARS IN CANCER BIOLOGY
- Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
- (2020) Michela Piezzo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
- (2020) Peter A. Fasching et al. BREAST
- Functional determinants of cell-cycle plasticity and sensitivity to CDK4/6 inhibition
- (2020) Vishnu Kumarasamy et al. CANCER RESEARCH
- Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
- (2020) C. Louwrens Braal et al. DRUGS
- Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis
- (2020) Yilun Li et al. World Journal of Surgical Oncology
- Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
- (2020) Zhen Li et al. Frontiers in Pharmacology
- Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
- (2020) Kamal Pandey et al. Cancers
- CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
- (2019) Laura M. Spring et al. Current Oncology Reports
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
- (2019) Aradhana Rani et al. Frontiers in Endocrinology
- Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
- (2019) Sobhani et al. Cells
- Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women
- (2019) Robert J Cersosimo AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer
- (2019) Joshua Z Drago et al. CLINICAL CANCER RESEARCH
- Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology
- (2019) Gabriele Di Sante et al. Expert Review of Anticancer Therapy
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer
- (2019) Richard S. Finn et al. CLINICAL CANCER RESEARCH
- Pathways to Endocrine Therapy Resistance in Breast Cancer
- (2019) Md. Moquitul Haque et al. Frontiers in Endocrinology
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway
- (2019) Tianqi Li et al. Artificial Cells Nanomedicine and Biotechnology
- Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
- (2019) Valentina Rossi et al. Cancers
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
- (2019) Keelan Z. Guiley et al. SCIENCE
- Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial
- (2018) M Arnedos et al. ANNALS OF ONCOLOGY
- A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer
- (2018) Hyun Joo Lee et al. CANCER LETTERS
- Redundant angiogenic signaling and tumor drug resistance
- (2018) Rajesh N. Gacche et al. DRUG RESISTANCE UPDATES
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
- (2018) Takashi Takeshita et al. Molecular Cancer
- Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
- (2018) Chrysiis Michaloglou et al. MOLECULAR CANCER THERAPEUTICS
- Luminal A Breast Cancer and Molecular Assays: A Review
- (2018) Jennifer J. Gao et al. ONCOLOGIST
- Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
- (2018) Silvia Paola Corona et al. Drug Design Development and Therapy
- Cyclin D1-mediated microRNA expression signature predicts breast cancer outcome
- (2018) Guangxue Wang et al. Theranostics
- Evaluation of Biomarkers in Multiple Ipsilateral Synchronous Invasive Breast Carcinomas
- (2018) Pooja Navale et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies
- (2018) Joseph A. Caruso et al. CANCER RESEARCH
- CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
- (2018) Shom Goel et al. TRENDS IN CELL BIOLOGY
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
- (2018) Kamal Pandey et al. INTERNATIONAL JOURNAL OF CANCER
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Fibroblast Growth Factor Antagonist Peptide Inhibits Breast Cancer in BALB/c Mice
- (2018) Mehrzad Jafarzadeh et al. Open Life Sciences
- Risk Factors and Preventions of Breast Cancer
- (2017) Yi-Sheng Sun et al. International Journal of Biological Sciences
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Recent advances of highly selective CDK4/6 inhibitors in breast cancer
- (2017) Hanxiao Xu et al. Journal of Hematology & Oncology
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA‐3 Results
- (2017) Sibylle Loibl et al. ONCOLOGIST
- Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
- (2017) Laura M. Spring et al. ONCOLOGIST
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Biological functions of CDK5 and potential CDK5 targeted clinical treatments
- (2017) Alison Shupp et al. Oncotarget
- Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer
- (2017) Gabriele Di Sante et al. Oncotarget
- Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
- (2017) Erik S. Knudsen et al. Oncotarget
- Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth
- (2017) Timothy G. Pestell et al. Oncotarget
- Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment
- (2017) Christina Demuth et al. Oncotarget
- Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
- (2017) John E. Bisi et al. Oncotarget
- Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
- (2017) Fengquan Chen et al. Anti-Cancer Agents in Medicinal Chemistry
- Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
- (2017) Ana Sahores et al. CURRENT CANCER DRUG TARGETS
- Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
- (2016) Sonya C Tate et al. BRITISH JOURNAL OF CANCER
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Cyclin-dependent kinase pathways as targets for womenʼs cancer treatment
- (2016) Gottfried E. Konecny CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Targeting the RB-E2F pathway in breast cancer
- (2016) J Johnson et al. ONCOGENE
- Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer
- (2016) Supipi Duffy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy
- (2016) Peter Csermely et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
- (2016) Luca Malorni et al. Oncotarget
- p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer
- (2016) Patrick Lebok et al. Oncotarget
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
- (2015) Christopher D. Hart et al. Nature Reviews Clinical Oncology
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Breast Cancer with CDK Inhibitors
- (2015) Erica L. Mayer Current Oncology Reports
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis
- (2015) Mathew C. Casimiro et al. Oncotarget
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1)
- (2014) Na Ye et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
- (2013) Karoline Kollmann et al. CANCER CELL
- ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice
- (2012) Mathew C. Casimiro et al. JOURNAL OF CLINICAL INVESTIGATION
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Targeting Aneuploidy for Cancer Therapy
- (2011) Eusebio Manchado et al. CELL
- Identification of Aneuploidy-Selective Antiproliferation Compounds
- (2011) Yun-Chi Tang et al. CELL
- Centrosome clustering and cyclin D1 gene amplification in double minutes are common events in chromosomal unstable bladder tumors
- (2010) Javier del Rey et al. BMC CANCER
- c-Jun Induces Mammary Epithelial Cellular Invasion and Breast Cancer Stem Cell Expansion
- (2010) Xuanmao Jiao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- C-jun Inhibits Mammary Apoptosis In Vivo
- (2010) Sanjay Katiyar et al. MOLECULAR BIOLOGY OF THE CELL
- Disruption of c-Jun Reduces Cellular Migration and Invasion through Inhibition of c-Src and Hyperactivation of ROCK II Kinase
- (2008) Xuanmao Jiao et al. MOLECULAR BIOLOGY OF THE CELL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started